Progesterone News and Research RSS Feed - Progesterone News and Research

Study debunks false reports surrounding risk of hormone therapy

Study debunks false reports surrounding risk of hormone therapy

For over a decade, hormone therapy (HT) has been a hot topic in medicine. Unfortunately, women are still confused and concerned about using HT after two federally-funded studies linked HT to potentially serious health risks. [More]
Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" to show benefit from anti-androgen therapies. [More]
Many women fail to understand risks of unapproved, untested bioidentical hormone therapies

Many women fail to understand risks of unapproved, untested bioidentical hormone therapies

From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society. [More]
Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Variants in fetus's DNA may trigger some early births

Variants in fetus's DNA may trigger some early births

Some babies seem to have a genetic predisposition to a higher risk of being born too soon, according to researchers in a study to be presented on Feb. 5 in an oral concurrent session at 8 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting in San Diego. [More]
New study examines the methylome of triple-negative breast cancer

New study examines the methylome of triple-negative breast cancer

The new study, published in Nature Communications, compares the breast cancer DNA 'methylome' with that of healthy individuals. The methylome provides a new picture of the genome and shows how it is epigenetically 'decorated' with methyl groups, a process known as DNA 'methylation'. [More]
Scientists identify strong link between beclin 1 gene and triple-negative breast cancer

Scientists identify strong link between beclin 1 gene and triple-negative breast cancer

UT Southwestern Medical Center scientists have identified a strong link between the most aggressive type of breast cancer and a gene that regulates the body's natural cellular recycling process, called autophagy. [More]
Fast HPLC screening methods used to detect steroids

Fast HPLC screening methods used to detect steroids

As the importance of steroids in the regulation of bioprocesses has increased so has the demand for fast screening methods for their detection. HPLC is a highly regarded analytical technique for pharmaceutical applications due to its unrivalled analytical validation characteristics; including accuracy, precision, limit of detection, specificity, linearity and range, and ruggedness. [More]
Study: Race and ethnicity may affect breast cancer diagnoses, survival

Study: Race and ethnicity may affect breast cancer diagnoses, survival

Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biological differences, according to a study in the January 13 issue of JAMA. [More]
New study shows that menstrual cycle may have an effect on nicotine cravings

New study shows that menstrual cycle may have an effect on nicotine cravings

The menstrual cycle appears to have an effect on nicotine cravings, according to a new study by Adrianna Mendrek of the University of Montreal and its affiliated Institut universitaire en santé mentale de Montréal. [More]
Even men undergo hormonal changes on way to fatherhood, study finds

Even men undergo hormonal changes on way to fatherhood, study finds

Impending fatherhood can lower two hormones--testosterone and estradiol--for men, even before their babies are born, a new University of Michigan study found. [More]
Study sheds light on clinical and biological characteristics of male breast cancer

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women. [More]
Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer. [More]
Progesterone treatment shows no clinical benefits in severe TBI patients

Progesterone treatment shows no clinical benefits in severe TBI patients

A study concluded that after five days of treatment with a novel formulation of progesterone acutely administered to patients with severe traumatic brain injury (TBI), showed no clinical benefits. [More]
Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine - better known as the anti-depressant Prozac - could hold the key to preventing PMS symptoms, an international team of researchers has found. [More]
Researchers identify possible prognostic biomarker in triple-negative breast cancer

Researchers identify possible prognostic biomarker in triple-negative breast cancer

"Triple-negative" breast cancer (TNBC) occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER-/PR-/HER2-). [More]
Mayo Clinic recommends genetic screening for patients with triple-negative breast cancer

Mayo Clinic recommends genetic screening for patients with triple-negative breast cancer

Most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2, a Mayo Clinic-led study has found. [More]
Researchers obtain detailed picture of how Gas5 RNA interacts with steroid hormone receptors

Researchers obtain detailed picture of how Gas5 RNA interacts with steroid hormone receptors

It arises from what scientists previously described as "junk DNA" or "the dark matter of the genome," but this gene is definitely not junk. [More]
March of Dimes calls for nationwide effort to reduce U.S. preterm births to 5.5% by 2030

March of Dimes calls for nationwide effort to reduce U.S. preterm births to 5.5% by 2030

The March of Dimes is calling for a nationwide effort to reduce U.S. preterm births to 5.5 percent of all live births by 2030. Seven other developed countries already have preterm birth rates below 6 percent, and 15 have rates below 7 percent. [More]